277 related articles for article (PubMed ID: 24025522)
1. Renal tumors: diagnostic and prognostic biomarkers.
Tan PH; Cheng L; Rioux-Leclercq N; Merino MJ; Netto G; Reuter VE; Shen SS; Grignon DJ; Montironi R; Egevad L; Srigley JR; Delahunt B; Moch H;
Am J Surg Pathol; 2013 Oct; 37(10):1518-31. PubMed ID: 24025522
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical diagnosis of renal neoplasms.
Truong LD; Shen SS
Arch Pathol Lab Med; 2011 Jan; 135(1):92-109. PubMed ID: 21204715
[TBL] [Abstract][Full Text] [Related]
3. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai J; Hamilton C; Shen SS; Ro JY; Krishnan B; Truong LD
Am J Clin Pathol; 2009 Mar; 131(3):393-404. PubMed ID: 19228645
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Alshenawy HA
Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789
[TBL] [Abstract][Full Text] [Related]
5. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features.
Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN
J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359
[TBL] [Abstract][Full Text] [Related]
6. [Pax-2 antigen expression in kidney tumours].
Vjestica JM; Marković-Lipkovski J; Tulić CD; Djokić MR; Segar BS; Cirović SL; Stojanović MM; Vuksanović AM
Acta Chir Iugosl; 2011; 58(4):15-20. PubMed ID: 22519185
[TBL] [Abstract][Full Text] [Related]
7. Useful markers for differential diagnosis of oncocytoma, chromophobe renal cell carcinoma and conventional renal cell carcinoma.
Geramizadeh B; Ravanshad M; Rahsaz M
Indian J Pathol Microbiol; 2008; 51(2):167-71. PubMed ID: 18603673
[TBL] [Abstract][Full Text] [Related]
8. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai Q; Javed R; Shen SS; Coffey D; Krishnan B; Truong LD
Arch Pathol Lab Med; 2010 Aug; 134(8):1121-9. PubMed ID: 20670131
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
10. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.
Zhou M; Roma A; Magi-Galluzzi C
Clin Lab Med; 2005 Jun; 25(2):247-57. PubMed ID: 15848735
[TBL] [Abstract][Full Text] [Related]
11. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10.
Sangoi AR; Karamchandani J; Kim J; Pai RK; McKenney JK
Adv Anat Pathol; 2010 Nov; 17(6):377-93. PubMed ID: 20966644
[TBL] [Abstract][Full Text] [Related]
12. Recent advances of immunohistochemistry for diagnosis of renal tumors.
Kuroda N; Tanaka A; Ohe C; Nagashima Y
Pathol Int; 2013 Aug; 63(8):381-90. PubMed ID: 23957913
[TBL] [Abstract][Full Text] [Related]
13. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
14. [Immunohistochemical profile of renal cell tumours].
Gutiérrez Olivares VM; González Torres LM; Hunter Cuartas G; Niebles De la Hoz MC
Rev Esp Patol; 2019; 52(4):214-221. PubMed ID: 31530404
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases.
Sangoi AR; Fujiwara M; West RB; Montgomery KD; Bonventre JV; Higgins JP; Rouse RV; Gokden N; McKenney JK
Am J Surg Pathol; 2011 May; 35(5):678-86. PubMed ID: 21490444
[TBL] [Abstract][Full Text] [Related]
16. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin.
Mentrikoski MJ; Wendroth SM; Wick MR
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):635-41. PubMed ID: 25279712
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical approach to the differential diagnosis of renal tumors.
Skinnider BF; Amin MB
Semin Diagn Pathol; 2005 Feb; 22(1):51-68. PubMed ID: 16512599
[TBL] [Abstract][Full Text] [Related]
19. CAIX and pax-8 Commonly Immunoreactive in Endolymphatic Sac Tumors: A Clinicopathologic Study of 26 Cases with Differential Considerations for Metastatic Renal Cell Carcinoma in von Hippel-Lindau Patients.
Thompson LDR; Magliocca KR; Andreasen S; Kiss K; Rooper L; Stelow E; Wenig BM; Bishop JA
Head Neck Pathol; 2019 Sep; 13(3):355-363. PubMed ID: 30291511
[TBL] [Abstract][Full Text] [Related]
20. Role of molecular markers in diagnosis and prognosis of renal cell carcinoma.
Martignoni G; Brunelli M; Gobbo S; Remo A; Ficarra V; Cossu-Rocca P; Pea M; Chilosi M; Menestrina F; Cheng L
Anal Quant Cytol Histol; 2007 Feb; 29(1):41-9. PubMed ID: 17375873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
